CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine
about
Antimalarial drug discovery - approaches and progress towards new medicines.Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivoVariation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax RelapsesAge, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children.Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers.Primaquine: the risks and the benefitsEffect of fluorescent dyes on in vitro-differentiated, late-stage Plasmodium falciparum gametocytes.Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects.Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjectsEnantioselective metabolism of primaquine by human CYP2D6.Differential CYP 2D6 metabolism alters primaquine pharmacokinetics.Human iPSC-derived hepatocyte-like cells support Plasmodium liver-stage infection in vitro.Targeting the erythrocytic and liver stages of malaria parasites with s-triazine-based hybrids.Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in CambodiaDevelopment of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infectionTafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytesGenetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.Primaquine treatment and relapse in Plasmodium vivax malariaThe metabolism of primaquine to its active metabolite is dependent on CYP 2D6Single-Dose Primaquine in a Preclinical Model of Glucose-6-Phosphate Dehydrogenase Deficiency: Implications for Use in Malaria Transmission-Blocking Programs.Management of relapsing Plasmodium vivax malariaTafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.Towards a Humanized Mouse Model of Liver Stage Malaria Using Ectopic Artificial Livers.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.The effect of SNPs in CYP450 in chloroquine/primaquine Plasmodium vivax malaria treatment.Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.The antimalarial drug primaquine targets Fe-S cluster proteins and yeast respiratory growthPrimaquine-thiazolidinones block malaria transmission and development of the liver exoerythrocytic forms.A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax.The in vivo and in vitro phase I metabolism of FYL-67, a novel oxazolidinone antibacterial drug, studied by LC-MS/MS.A newly validated high-performance liquid chromatography method with diode array ultraviolet detection for analysis of the antimalarial drug primaquine in the blood plasma.A novel immortalized hepatocyte-like cell line (imHC) supports in vitro liver stage development of the human malarial parasite Plasmodium vivax.Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13C stable isotope labeling.Factors Affecting Primaquine Combination Treatment in Malaria Patients in Selangor, Malaysia.Factors Affecting Primaquine Combination Treatment in Malaria Patients in Selangor, Malaysia.Enantiospecific pharmacokinetics and drug–drug interactions of primaquine and blood-stage antimalarial drugs
P2860
Q27693245-FD9BB9E8-E5B5-4C9E-9F1E-5E6F1DC254C2Q28544459-0D34E887-7790-4413-A26A-84834A27D119Q28553162-C20F68F5-8B85-47B0-93CD-4DD68F0B4855Q33601837-AEB8D0E1-83E8-4E67-A3DB-33D5E0FADADDQ34058282-EBD46716-1C93-4880-89DE-FFC19337787FQ34503631-C4237818-D515-4AFC-A9D4-61F3AC1A0278Q34597823-BA7ABCAD-0287-4D62-B36E-D483B059633BQ34597891-F4A61806-E832-4187-90EB-F65F22B9F00BQ34922652-62E34122-9692-4A2A-9C0E-39DB467D69B6Q34994945-F22C7F8D-D2FE-4DB7-BEC4-AF1BE28D0B1EQ35169119-59B17BEE-9C19-4245-B4DD-194C0583B994Q35222586-F933B394-6CD8-4D8E-A418-9C2259ACC3ACQ35580148-58167A2C-400C-43FF-8EBF-F2956BD90815Q35746028-383F3D7E-DC38-403A-A248-3B2BA733E30FQ36175374-3A9F473C-5F35-4C17-8166-70BEB7342137Q36320042-07ABF7C4-FC76-421E-A355-5B26D6B6AE23Q36591835-24488FE9-B143-4F8A-900C-ED80AC05BFFFQ36815343-5298E74E-8114-4FF9-AC01-3CB418FA6687Q36825513-09721D6D-89B0-4B5D-9410-63D731A603BAQ36907360-085BD7D0-62C1-4462-BE06-6FA0F875701DQ36909121-F0B63062-77F2-4163-81E5-3A07C05E5A31Q36945581-06861CED-FECC-4629-92BC-D95D1AEC3460Q37287860-F2C8D15E-2567-4AA5-AD19-1C1512EAE2A4Q37290599-BAE8FC38-59E7-4F18-90F6-32A2CFC2F073Q37485056-38165E43-8C91-4943-8D6B-D408061478E0Q37731353-FABCE3A6-97CA-45FC-ABB2-C3A8F4BFAC59Q38800092-BAFFCAE1-FE83-4850-981F-C88EA82FE834Q38808206-80BBCF26-DA2B-485B-86B5-BDCF4616E0D0Q38827021-FFAD45DC-DD57-4528-9FBC-E5CB32930D7FQ39158070-9DB91EF6-C53E-4114-95D4-D334D3F90EBEQ40300583-5DE1D03F-6AAA-4360-8394-4AC7B011D575Q42971169-8C6BB2D5-F8B1-4408-A3BF-BE533692F87FQ46653380-303CBCC7-011A-45AF-8250-4FF393B77459Q47627038-87F6B7D1-C2E5-47B1-B07D-76BE31728CB4Q48023325-C6A0A204-45B1-4EE2-A1CD-6FD839E35E89Q48032573-A48587A2-7006-428F-A523-63FA79D11610Q49641633-CE5DB6EC-4FAF-4FE2-ADEC-AB993AA72CF5Q49885607-7DA16548-74D4-4C4C-86B0-4D48D7C15541Q57420827-D4C940FA-7516-403D-8C90-777233DEE5FB
P2860
CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@ast
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@en
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@en-gb
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@nl
type
label
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@ast
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@en
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@en-gb
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@nl
prefLabel
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@ast
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@en
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@en-gb
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@nl
P2093
P2860
P3181
P356
P1433
P1476
CYP450 phenotyping and accurat ...... anti-malarial drug primaquine
@en
P2093
Brandon S Pybus
Chau Vuong
Colin Ohrt
Gregory A Reichard
James A Ferguson
Jason C Sousa
Larry A Walker
Michael P Kozar
Rebecca Barnhart
Richard J Sciotti
P2860
P2888
P3181
P356
10.1186/1475-2875-11-259
P407
P577
2012-01-01T00:00:00Z
P5875
P6179
1034584340